<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04053764</url>
  </required_header>
  <id_info>
    <org_study_id>CSEG101A2203</org_study_id>
    <secondary_id>2018-003608-38</secondary_id>
    <nct_id>NCT04053764</nct_id>
  </id_info>
  <brief_title>Study Exploring the Effect of Crizanlizumab on Kidney Function in Patients With Chronic Kidney Disease Caused by Sickle Cell Disease</brief_title>
  <acronym>STEADFAST</acronym>
  <official_title>A Phase II, Multicenter, Randomized, Open Label Two Arm Study Comparing the Effect of Crizanlizumab + Standard of Care to Standard of Care Alone on Renal Function in Sickle Cell Disease Patients ≥ 16 Years With Chronic Kidney Disease Due to Sickle Cell Nephropathy</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Novartis Pharmaceuticals</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Novartis</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The goal of the study is to compare the efficacy and safety of crizanlizumab + standard of
      care to standard of care alone on renal function in sickle cell disease patients ≥ 16 years
      with chronic kidney disease due to sickle cell nephropathy.
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">December 10, 2019</start_date>
  <completion_date type="Anticipated">February 27, 2023</completion_date>
  <primary_completion_date type="Anticipated">June 6, 2022</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Percentage of patients with ≥ 30% decrease in albuminuria (ACR)</measure>
    <time_frame>Baseline to 12 months</time_frame>
    <description>To evaluate the effect of crizanlizumab + standard of care compared to standard of care alone on albuminuria (ACR) decrease</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Mean change in albuminuria (ACR)</measure>
    <time_frame>baseline to 3, 6, 9, and 12 months</time_frame>
    <description>To evaluate the effect of crizanlizumab + standard of care compared to standard of care alone on change in albuminuria (ACR)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percentage of patients with ≥ 30% decrease in albuminuria (ACR)</measure>
    <time_frame>Baseline to 6 months</time_frame>
    <description>To evaluate the effect of crizanlizumab + standard of care compared to standard of care alone on albuminuria (ACR) decrease</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percentage of patients with ≥ 20% improvement of protein to creatinine ratio (PCR)</measure>
    <time_frame>Baseline to 12 months</time_frame>
    <description>To evaluate the effect of crizanlizumab + standard of care compared to standard of care alone on protein to creatinine ratio (PCR)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percentage of patients with a stable (within ± 20% change) protein to creatinine ratio (PCR)</measure>
    <time_frame>Baseline to 12 months</time_frame>
    <description>To evaluate the effect of crizanlizumab + standard of care compared to standard of care alone on protein to creatinine ratio (PCR)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percentage change in estimated glomerular filtration rate (eGFR)</measure>
    <time_frame>Baseline to 3, 6, 9 and 12 months</time_frame>
    <description>To evaluate the effect of crizanlizumab + standard of care compared to standard of care alone on the percentage change in estimated glomerular filtration rate (eGFR)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Slope of albumin to creatinine ratio (ACR) decline</measure>
    <time_frame>Baseline, 3, 6, 9, and 12 months</time_frame>
    <description>To evaluate the effect of crizanlizumab + standard of care compared to standard of care alone on albumin to creatinine ratio (ACR) decline rate</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Slope of estimated glomerular filtration rate (eGFR) decline</measure>
    <time_frame>Baseline to 3, 6, 9 and 12 months</time_frame>
    <description>To evaluate the effect of crizanlizumab + standard of care compared to standard of care alone on estimated glomerular filtration rate (eGFR) decline rate</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percentage of patients with progression of chronic kidney disease (CKD)</measure>
    <time_frame>Baseline to 12 months</time_frame>
    <description>To evaluate the effect of crizanlizumab + standard of care compared to standard of care alone on the progression of chronic kidney disease (CKD)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Immunogenicity: measurement of anti-drug antibodies (ADA) to crizanlizumab</measure>
    <time_frame>Baseline to follow-up period, at select time points approx. 1 year and 4 months</time_frame>
    <description>To assess the immunogenicity of crizanlizumab over the study period</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Annualized rate of visits to emergency room and hospitalizations</measure>
    <time_frame>Baseline to follow-up period, approx. 1 year and 4 months</time_frame>
    <description>To evaluate healthcare resource utilization (visits to emergency room and hospitalizations) due to Acute Kidney Injury (AKI) events, Vaso-occlusive crisis (VOCs), or other Sickle Cell Disease (SCD) complications.</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">170</enrollment>
  <condition>Sickle Cell Disease (SCD)</condition>
  <arm_group>
    <arm_group_label>crizanlizumab + standard of care</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>5 mg/kg by intravenous infusion at Week 1 Day 1, Week 3 Day 1 and Day 1 of every 4-week cycle until Week 51 in addition to their usual standard of care treatment.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>standard of care</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Patients in the standard of care alone arm will continue to receive their usual standard of care treatment.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Crizanlizuamb</intervention_name>
    <description>Crizanlizumab is a concentrate for solution for infusion, i.v. use. Supplied in single use 10 mL vials at a concentration of 10 mg/mL. One vial contains 100 mg of crizanlizumab</description>
    <arm_group_label>crizanlizumab + standard of care</arm_group_label>
    <other_name>SEG101</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Standard of Care</intervention_name>
    <description>HU/HC (hydroxyurea/hydroxycarbamide), ACE (angiotensin-converting enzyme)inhibitors, and ARBs (angiotensin-receptor blocker)</description>
    <arm_group_label>crizanlizumab + standard of care</arm_group_label>
    <arm_group_label>standard of care</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Confirmed diagnosis of SCD (HbSS and HbSβ0-thal SCD genotypes are eligible)

          -  Patients with eGFR ≥ 45 to ≤ 120 mL/min/1.73 m2 based on CKD EPI formula

          -  Patients with ACR of ≥ 100 to &lt; 2000 mg/g

          -  Receiving standard of care drug(s) for SCD and/or CKD for at least 6 months prior to
             study entry

          -  Hb ≥ 4.0 g/dL, absolute neutrophil count (ANC) ≥ 1.0 x 109/L, and platelet count ≥ 75
             x 109/L

          -  Written informed consent (or assent/ parental consent for minor subjects) prior to any
             screening procedures

        Exclusion Criteria:

          -  History of stem cell transplant

          -  Patients with evidence of AKI within 3 months of study entry

          -  Blood pressure &gt; 140/90 mmHg despite treatment

          -  Patients undergoing hemodialysis

          -  Received blood products within 30 days of Week 1 Day 1

          -  Participating in a chronic transfusion program

          -  History of kidney transplant

          -  Patients with hypoalbuminemia

        Other protocol-defined inclusion/exclusion criteria may apply
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>16 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Novartis Pharmaceuticals</last_name>
    <role>Study Director</role>
    <affiliation>Novartis Pharmaceuticals</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Novartis Pharmaceuticals</last_name>
    <phone>1-888-669-6682</phone>
    <email>novartis.email@novartis.com</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Novartis Pharmaceuticals</last_name>
    <phone>+41613241111</phone>
    <email>novartis.email@novartis.com</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>University of Alabama Birmingham</name>
      <address>
        <city>Birmingham</city>
        <state>Alabama</state>
        <zip>35233</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Ronson Washington</last_name>
      <phone>843-792-1815</phone>
      <email>ronsonwashington@uabmc.edu</email>
    </contact>
    <investigator>
      <last_name>Julie Kanter-Washko</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Our Lady of the Lake Regional Medical Center</name>
      <address>
        <city>Baton Rouge</city>
        <state>Louisiana</state>
        <zip>70809</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Emily Perdue</last_name>
      <phone>225-214-3638</phone>
      <email>Emily.Perdue@fmolhs.org</email>
    </contact>
    <investigator>
      <last_name>Vince Cataldo</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Rio de Janeiro</city>
        <state>RJ</state>
        <zip>20.211-030</zip>
        <country>Brazil</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Sao Paulo</city>
        <state>SP</state>
        <zip>05403 000</zip>
        <country>Brazil</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Sao Paulo</city>
        <state>SP</state>
        <zip>08270-070</zip>
        <country>Brazil</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Porto Alegre</city>
        <zip>90035-003</zip>
        <country>Brazil</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Creteil</city>
        <zip>94000</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Patras</city>
        <zip>265 00</zip>
        <country>Greece</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Barcelona</city>
        <state>Catalunya</state>
        <zip>08035</zip>
        <country>Spain</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Madrid</city>
        <zip>28009</zip>
        <country>Spain</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Madrid</city>
        <zip>28034</zip>
        <country>Spain</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Adana</city>
        <zip>01250</zip>
        <country>Turkey</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Antakya / Hatay</city>
        <zip>31100</zip>
        <country>Turkey</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>London</city>
        <zip>SE5 9RS</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>London</city>
        <zip>W12 0HS</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location_countries>
    <country>Brazil</country>
    <country>France</country>
    <country>Greece</country>
    <country>Spain</country>
    <country>Turkey</country>
    <country>United Kingdom</country>
    <country>United States</country>
  </location_countries>
  <verification_date>July 2020</verification_date>
  <study_first_submitted>August 9, 2019</study_first_submitted>
  <study_first_submitted_qc>August 9, 2019</study_first_submitted_qc>
  <study_first_posted type="Actual">August 12, 2019</study_first_posted>
  <last_update_submitted>July 17, 2020</last_update_submitted>
  <last_update_submitted_qc>July 17, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">July 20, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>SEG101</keyword>
  <keyword>SCD</keyword>
  <keyword>Crizanlizumab</keyword>
  <keyword>Sickle cell nephropathy</keyword>
  <keyword>chronic kidney disease</keyword>
  <keyword>CKD</keyword>
  <keyword>albuminuria (ACR)</keyword>
  <keyword>renal function</keyword>
  <keyword>standard of care</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Kidney Diseases</mesh_term>
    <mesh_term>Renal Insufficiency, Chronic</mesh_term>
    <mesh_term>Anemia, Sickle Cell</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>Yes</sharing_ipd>
    <ipd_description>Novartis is committed to sharing with qualified external researchers, access to patient-level data and supporting clinical documents from eligible studies. These requests are reviewed and approved by an independent expert panel on the basis of scientific merit. All data provided is anonymized to respect the privacy of patients who have participated in the trial in line with applicable laws and regulations.
This trial data is currently available according to the process described on www.clinicalstudydatarequest.com.</ipd_description>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

